Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

• Main Authors: Yu-Yun Shao, Shen-Yung Wang, Shi-Ming Lin, Kuan-Yang Chen, Jeng-Hwei Tseng, Ming-Chih Ho, Rheun-Chuan Lee, Po-Chin Liang, Li-Ying Liao, Kai-Wen Huang, Jui-Ting Hu, Ja-Der Liang, Kwong-Ming Kee, Chih-Lin Lin, Chung-Kwe Wang, Sheng-Nan Lu, Jing-Houng Wang, Wei-Chen Lee, Chien-Hung Chen, Chun-Jen Liu, Yi-Hsiang Huang, Chia-Chi Wang, Tsang-En Wang, Po-Heng Chuang, Chia-Yen Dai, Chiun Hsu, San-Chi Chen, Chia-Hsun Hsieh
• Format: Article
• Language: English
• Published: Elsevier 2021-04-01
• Series: Journal of the Formosan Medical Association
• Subjects: Hepatocellular carcinoma; Guideline; Surveillance; Diagnosis; Systemic treatment
• Online Access: http://www.sciencedirect.com/science/article/pii/S0929664620305313

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan had established a management consensus guideline in 2016. The current recommendations focus on updating critical issues regarding the management of HCC, including surveillance, diagnosis, and systemic treatment. For surveillance, the updated guideline suggests the role of dynamic computed tomography or magnetic resonance imaging and contrast-enhanced ultrasound (CEUS) in selected patients. For diagnosis, this update incorporates CEUS and recognizes the role of gadoxetic acid–enhanced magnetic resonance imaging. For systemic therapy, the updated guideline summarizes the multiple choices of targeted therapy, immune checkpoint inhibitors, and the combination of both. Through this update of the management consensus guideline, patients with HCC can benefit from receiving optimal diagnostic and therapeutic modalities.